Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease ~ Achieved statistically significant...
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.735 | 4.40383463152 | 16.69 | 17.89 | 16.22 | 485 | 16.49761004 | DE |
| 4 | 11.269 | 183.057179987 | 6.156 | 17.89 | 6.154 | 4261 | 14.61908448 | DE |
| 12 | 12.467 | 251.452198467 | 4.958 | 17.89 | 4.958 | 1749 | 12.5690584 | DE |
| 26 | 13.561 | 350.957556936 | 3.864 | 17.89 | 3.548 | 1815 | 9.69399969 | DE |
| 52 | 11.035 | 172.69170579 | 6.39 | 17.89 | 3.548 | 1276 | 8.44272565 | DE |
| 156 | -0.525 | -2.92479108635 | 17.95 | 25.61 | 3.548 | 852 | 8.50296085 | DE |
| 260 | -14.035 | -44.6122059758 | 31.46 | 32.78 | 3.548 | 581 | 9.70057369 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
